Neurofilament light protein may be able to determine when an athlete who's suffered a concussion can safely return to playing again, researchers said.
The partners will develop an amyloid β 42/40 ratio assay to identify patients who may benefit from treatment with Janssen's drug called atabecestat.
The firm expects to build out a menu for the reader, which will automate results reporting for colorimetric- and fluorescence-based tests.
Pivoting from a technology that it deemed wasn't robust enough, Confer Health is now designing a platform to enable broad-scale testing at home.
They have developed a prototype assay that requires only a drop of blood and relies on an immunoreaction that blocks electrons to enable CRP measurement.
To identify the superbug, the firm used a rapid test that assigns microbial DNA fingerprints to reveal the clonal identity of a bacterial strain in patient samples.
The USF researchers have developed an inexpensive mobile prototype and measured progesterone concentrations at levels of performance comparable to standard ELISAs.
Its CEO said the firm wants to make its tissue classifier the clinical standard for stratifying patients at risk of getting esophageal cancer.
The researchers improved diagnostic sensitivity one hundredfold by moving the source of terahertz waves close to a biological sample in a microchannel.
The device uses neutrophil movement and its correlation with infection to detect sepsis. A commercial version could be several years away, however.